With Focus on the 'Undruggable,' Biotech Raises $88.5M Series B from IPO-minded Investors

https://endpts.com/months-after-amgens-landmark-kras-approval-a-bay-area-startup-readies-a-next-gen-candidate-for-the-clinic/
Join the IPIRA Mailing List

 

 
 
 
 

 

Accessibility | Nondiscrimination | Privacy